-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HC Wainwright Trims Cardiff Oncology (NASDAQ:CRDF) Target Price to $14.00
HC Wainwright Trims Cardiff Oncology (NASDAQ:CRDF) Target Price to $14.00
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a report issued on Friday morning, The Fly reports. They currently have a buy rating on the stock.
Several other analysts also recently weighed in on CRDF. Piper Sandler dropped their target price on shares of Cardiff Oncology from $7.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, September 13th. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $9.00 to $6.00 and set an outperform rating for the company in a research note on Monday, August 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $9.75.
Get Cardiff Oncology alerts:Cardiff Oncology Stock Performance
CRDF stock opened at $1.73 on Friday. The firm has a market cap of $74.92 million, a PE ratio of -1.94 and a beta of 1.38. The firm's 50 day moving average price is $2.51 and its 200-day moving average price is $2.13. Cardiff Oncology has a one year low of $1.13 and a one year high of $7.63.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. Cardiff Oncology had a negative net margin of 9,841.41% and a negative return on equity of 28.82%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts predict that Cardiff Oncology will post -1.04 EPS for the current fiscal year.Insider Buying and Selling
In other news, CFO James E. Levine bought 30,000 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chief financial officer now owns 60,000 shares in the company, valued at approximately $93,600. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.50% of the company's stock.
Hedge Funds Weigh In On Cardiff Oncology
A number of institutional investors and hedge funds have recently modified their holdings of CRDF. Quantbot Technologies LP purchased a new stake in Cardiff Oncology in the first quarter valued at $28,000. LPL Financial LLC lifted its position in Cardiff Oncology by 17.9% in the second quarter. LPL Financial LLC now owns 26,384 shares of the company's stock valued at $58,000 after acquiring an additional 3,998 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cardiff Oncology in the first quarter valued at $62,000. Price T Rowe Associates Inc. MD lifted its position in Cardiff Oncology by 69.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company's stock valued at $80,000 after acquiring an additional 15,020 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter valued at $93,000. Institutional investors and hedge funds own 20.70% of the company's stock.
Cardiff Oncology Company Profile
(Get Rating)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Featured Articles
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a report issued on Friday morning, The Fly reports. They currently have a buy rating on the stock.
据The Fly报道,在周五上午发布的一份报告中,加的夫肿瘤公司(纳斯达克代码:CRDF-GET评级)被HC Wainwright公司的目标价从22.00美元下调至14.00美元。他们目前对该股的评级为买入。
Several other analysts also recently weighed in on CRDF. Piper Sandler dropped their target price on shares of Cardiff Oncology from $7.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, September 13th. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $9.00 to $6.00 and set an outperform rating for the company in a research note on Monday, August 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $9.75.
其他几位分析师最近也加入了对CRDF的看法。派珀·桑德勒在9月13日星期二的一份报告中将卡迪夫肿瘤公司的股票目标价从7.00美元下调至5.00美元,并为该公司设定了增持评级。罗伯特·W·贝尔德在8月29日星期一的一份研究报告中将加的夫肿瘤公司的股票目标价从9.00美元下调至6.00美元,并为该公司设定了表现优于大盘的评级。根据MarketBeat.com的数据,五位股票研究分析师对该股的评级为买入,该股的平均评级为买入,共识目标价为9.75美元。
Cardiff Oncology Stock Performance
加的夫肿瘤学股票表现
CRDF stock opened at $1.73 on Friday. The firm has a market cap of $74.92 million, a PE ratio of -1.94 and a beta of 1.38. The firm's 50 day moving average price is $2.51 and its 200-day moving average price is $2.13. Cardiff Oncology has a one year low of $1.13 and a one year high of $7.63.
CRDF股票上周五开盘报1.73美元。该公司市值为7492万美元,市盈率为-1.94,贝塔系数为1.38。该公司的50日移动均线价格为2.51美元,200日移动均线价格为2.13美元。加的夫肿瘤学的一年低点为1.13美元,一年高位为7.63美元。
Insider Buying and Selling
内幕买卖
In other news, CFO James E. Levine bought 30,000 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chief financial officer now owns 60,000 shares in the company, valued at approximately $93,600. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.50% of the company's stock.
在其他新闻方面,首席财务官詹姆斯·E·莱文在9月16日星期五的一笔交易中购买了30,000股该公司股票。股票是以每股1.56美元的平均价格购买的,总交易额为46,800.00美元。收购完成后,首席财务官现在拥有该公司60,000股股份,价值约93,600美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的,用户可以通过以下链接访问该文件。内部人士持有该公司3.50%的股份。
Hedge Funds Weigh In On Cardiff Oncology
对冲基金对卡迪夫肿瘤学的看法
A number of institutional investors and hedge funds have recently modified their holdings of CRDF. Quantbot Technologies LP purchased a new stake in Cardiff Oncology in the first quarter valued at $28,000. LPL Financial LLC lifted its position in Cardiff Oncology by 17.9% in the second quarter. LPL Financial LLC now owns 26,384 shares of the company's stock valued at $58,000 after acquiring an additional 3,998 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cardiff Oncology in the first quarter valued at $62,000. Price T Rowe Associates Inc. MD lifted its position in Cardiff Oncology by 69.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company's stock valued at $80,000 after acquiring an additional 15,020 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter valued at $93,000. Institutional investors and hedge funds own 20.70% of the company's stock.
一些机构投资者和对冲基金最近调整了对CRDF的持股。Quantbot Technologies LP在第一季度购买了加的夫肿瘤公司的新股份,价值2.8万美元。LPL Financial LLC在第二季度将其在加的夫肿瘤学的地位提高了17.9%。LPL Financial LLC现在拥有26,384股该公司的股票,价值58,000美元,在上个季度额外购买了3,998股。XTX Topco Ltd在第一季度收购了加的夫肿瘤学公司的新股份,价值6.2万美元。Price T Rowe Associates Inc.MD在第二季度将其在加的夫肿瘤学的地位提高了69.9%。Price T Rowe Associates Inc.MD现在拥有36,500股该公司股票,价值80,000美元,此前该公司在上个季度又收购了15,020股。最后,GSA Capital Partners LLP在第四季度购买了加的夫肿瘤公司的新股份,价值93,000美元。机构投资者和对冲基金持有该公司20.70%的股票。
Cardiff Oncology Company Profile
加的夫肿瘤学公司简介
(Get Rating)
(获取评级)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
加的夫肿瘤学公司是一家临床阶段的肿瘤学公司,在加利福尼亚州为癌症患者开发药物治疗。它的主要候选药物是onvansertib,一种用于抗癌治疗的口服选择性Polo-like Kinase 1抑制剂;CY140,一种PLK1、PLK2和PLK3的抑制剂,正处于实体肿瘤和白血病的1/2期研究;转移性结直肠癌,正在进行临床试验;以及trov-054,是FOLFIRI和贝伐单抗的1b/2期药物。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免费获取StockNews.com关于卡迪夫肿瘤学的研究报告(CRDF)
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受加的夫肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对加的夫肿瘤学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧